Biomodulation induced by fluorescent light energy versus standard of care in venous leg ulcers: a retrospective study

2019 ◽  
Vol 28 (11) ◽  
pp. 730-736 ◽  
Author(s):  
Valentina Dini ◽  
Agata Janowska ◽  
Giulia Davini ◽  
Jean-Charles Kerihuel ◽  
Stéphane Fauverghe ◽  
...  
Keyword(s):  
Wound Care ◽  
Standard Of Care ◽  
Light Energy ◽  
Fluorescent Light ◽  
Wound Age ◽  
Leg Ulcers ◽  
Venous Leg Ulcers ◽  
Wound Breakdown ◽  
And Gender ◽  
Matching Criteria

Objective: The recently completed EUREKA study confirmed the efficacy and safety profile of fluorescent light energy (FLE) in treating hard-to-heal wounds. To supplement the EUREKA prospective, observational, uncontrolled trial results, researchers selected one of the EUREKA clinical centres to conduct a retrospective analysis of matching wound care data for 46 venous leg ulcers (VLU) patients who had received standard wound care over a five-year period, compared with 10 EUREKA VLU subjects. Method: The study centre selected 46 patients with VLUs based on the matching criteria (wound age and size, patient's age and gender). They compared the healing rates of these matching VLUs with 10 VLU patients treated at the same centre during the EUREKA study. Results: The EUREKA patients had larger and significantly older wounds (p<0.05) and significantly more risk factors (p<0.05) than the matching wounds. However, they had better outcomes (EUREKA: 40% versus matching group: 7% for full wound closure by 16 weeks). No wound breakdown was observed at 16 weeks in the EUREKA group, compared with 25% in the matching group. No EUREKA patient developed infections requiring antibiotics, compared with 37% in the matching group. EUREKA wounds had a mean relative wound area regression (RWAR) of 32% at week six and 50% at week 16, compared with −3% at week six and −6% at week 16 for the matching group. Conclusion: These findings show that the system based on FLE was well-tolerated and efficacious, with better clinical outcome results compared with the wounds analysed in this retrospective matching study and treated with standard of care alone.

Treatment of venous leg ulcers using bilayered living cellular construct

2020 ◽  
Vol 9 (13) ◽  
pp. 907-918
Author(s):  
Aseel Bin Sawad ◽  
Fatema Turkistani
Keyword(s):  
Healthcare System ◽  
Cost Savings ◽  
Standard Of Care ◽  
Healthcare Resource Utilization ◽  
Psychological Status ◽  
Leg Ulcers ◽  
Venous Leg Ulcers ◽  
Time Period ◽  
The Us ◽  
Economic Analyses

Background: Venous leg ulcers (VLUs) present a significant economic burden on the US healthcare system and payers (US$14.9 billion). Aim: To evaluate the quality of life (QoL) of patients with VLUs; to analyze the limitations of standard of care (SOC) for VLUs; and to explain how using bilayered living cellular construct (BLCC) with SOC for treatment of VLUs can help heal more VLUs faster (than using SOC alone) as well as help improve QoL and help reduce the burden on the US healthcare system and payers. Materials & methods: This is a review study. The search was conducted in February 2020 by way of electronic databases to find relevant articles that provided information related to QoL of patients with VLUs, limitations of SOC for VLUs and economic analyses of using BLCC for treatment of VLUs. Results: VLUs impact patients’ physical, functional and psychological status and reduce QoL. A total 75% of VLU patients who used SOC alone failed to achieve healing in a timely fashion, which led to increased healthcare costs and healthcare resource utilization. Although the upfront cost is high, the greater effectiveness of BLCC offsets the added cost of the product during the time period of the studies. Therefore, BLCC helps to improve the QoL of VLU patients. As an example, for every 100 VLU patients in a healthcare plan, the use of BLCC can create cost savings of US$1,349,829.51. Conclusion: Payers’ coverage of BLCC results in reduction of the overall medical cost for treating VLU patients.

Randomized Controlled Trial Comparing Collagen/Oxidized Regenerated Cellulose/Silver to Standard of Care in the Management of Venous Leg Ulcers

2017 ◽  
Vol 30 (10) ◽  
pp. 464-468 ◽  
Author(s):  
Breda M. Cullen ◽  
Thomas E. Serena ◽  
Molly C. Gibson ◽  
Robert J. Snyder ◽  
Jason R. Hanft ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Standard Of Care ◽  
Regenerated Cellulose ◽  
Leg Ulcers ◽  
Oxidized Regenerated Cellulose ◽  
Venous Leg Ulcers ◽  
Randomized Controlled

More Frequent Visits to Wound Care Clinics Result in Faster Times to Close Diabetic Foot and Venous Leg Ulcers

2012 ◽  
Vol 25 (11) ◽  
pp. 494-501 ◽  
Author(s):  
Robert A. Warriner ◽  
James R. Wilcox ◽  
Marissa J. Carter ◽  
Deborah G. Stewart
Keyword(s):  
Diabetic Foot ◽  
Wound Care ◽  
Leg Ulcers ◽  
Venous Leg Ulcers

scholarly journals Health service costs of treating venous leg ulcers in the UK: evidence from a cross-sectional survey based in the north west of England

BMJ Open ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. e056790
Author(s):  
Sean Urwin ◽  
Jo C Dumville ◽  
Matt Sutton ◽  
Nicky Cullum
Keyword(s):  
Resource Use ◽  
Wound Care ◽  
Leg Ulcer ◽  
Leg Ulcers ◽  
Venous Leg Ulcer ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Venous Leg Ulcers ◽  
Annual Prevalence ◽  
The Uk

ObjectivesTo estimate and examine the direct healthcare costs of treating people with open venous leg ulcers in the UK.DesignCost-of-illness study.SettingA cross-sectional survey of nine National Health Service community locales over 2-week periods in 2015/2016.MethodsWe examined the resource use and prevalence of venous leg ulcer treatment in the community. Examination of variation in these obtained costs was performed by ordinary least squares regression. We used additional resource use information from a randomised control trial and extrapolated costs to the UK for an annual period.ResultsThe average 2-week per person cost of treating patients where a venous leg ulceration was the primary (most severe) wound was estimated at £166.39 (95% CI £157.78 to £175.00) with community staff time making up over half of this amount. Costs were higher where antimicrobial dressings were used and where wound care was delivered in the home. Among those with any recorded venous leg ulcer (primary and non-primary), we derived a point prevalence of 3.2 per 10 000 population and estimated that the annual prevalence could be no greater than 82.4 per 10 000 population. We estimated that the national cost of treating a venous leg ulcer was £102 million with a per person annual cost at £4787.70.ConclusionOur point prevalence figures are in line with the literature. However, our annual prevalence estimations and costs are far lower than those reported in recent literature which suggests that the costs of treating venous leg ulcers are lower than previously thought. Movement towards routinely collected and useable community care activity would help provide a transparent and deeper understanding of the scale and cost of wound care in the UK.

ReadyWrap®: case studies in practice

2019 ◽  
Vol 24 (Sup10) ◽  
pp. S24-S31
Author(s):  
Alison Schofield
Keyword(s):  
Case Studies ◽  
Chronic Wounds ◽  
Wound Care ◽  
Compression Therapy ◽  
Self Management ◽  
Leg Ulcers ◽  
Compression Garments ◽  
Venous Leg Ulcers ◽  
Good Concordance

The cost that chronic wound care imposes on both patients and health services worldwide is well recognised. Most patients with venous leg ulcers require compression therapy over the long term, for both treatment as well as to prevent recurrence of these wounds. Caring for patients with chronic wounds makes up a large part of the workload for district and community nurses, and encouraging self-management among patients is a worthwhile effort to limit the costs and resources directed for this purpose. The present article describes the practical use of the ReadyWrap range of compression garments, which are available in various different styles, and aid patients, their families and carers in the self-management of venous leg ulcers. These products are designed with their long-term use in mind, and, as described in the case studies in this article, patients show good concordance to compression therapy involving ReadyWrap.

scholarly journals Personalising wound care: A gene expression signature for predicting clinical outcomes of venous leg ulcers

2015 ◽  
Vol 23 ◽  
pp. S20
Author(s):  
D. Bosanquet ◽  
A. Sanders ◽  
E. Cox ◽  
F. Ruge ◽  
J. Lane ◽  
...  
Keyword(s):  
Gene Expression ◽  
Clinical Outcomes ◽  
Wound Care ◽  
Gene Expression Signature ◽  
Leg Ulcers ◽  
Expression Signature ◽  
Venous Leg Ulcers

Randomized standard-of-care-controlled trial of a silica gel fibre matrix in the treatment of chronic venous leg ulcers

2014 ◽  
Vol 24 (2) ◽  
pp. 210-216 ◽  
Author(s):  
Anneke Brown ◽  
Matthias Augustin ◽  
Michael Jünger ◽  
Markus Zutt ◽  
Joachim Dissemond ◽  
...  
Keyword(s):  
Silica Gel ◽  
Controlled Trial ◽  
Standard Of Care ◽  
Leg Ulcers ◽  
Venous Leg Ulcers ◽  
Fibre Matrix

scholarly journals Venous Leg Ulcers: Advanced Therapies and New Technologies

Biomedicines ◽  
2021 ◽  
Vol 9 (11) ◽  
pp. 1569
Author(s):  
Hubert Aleksandrowicz ◽  
Agnieszka Owczarczyk-Saczonek ◽  
Waldemar Placek
Keyword(s):  
New Technologies ◽  
Platelet Rich Plasma ◽  
Standard Of Care ◽  
Intermittent Pneumatic Compression ◽  
Venous Ulcer ◽  
Leg Ulcers ◽  
Plasma Therapy ◽  
Cell Therapies ◽  
Venous Leg Ulcers ◽  
Advanced Therapies

The prevalence of venous leg ulcers (VLUs) differs between 1.5% and 3% in the general population. The challenge in treating VLUs is common recurrence. Moreover, VLUs can be resistant to healing, despite appropriate treatment. In these cases, advanced wound therapies should be considered. The number of new technologies, applied in VLUs treatment, has increased in the last years. These therapies include biophysical interventions such as ultrasound therapy, electrical stimulations, electromagnetic therapy, or phototherapy. Furthermore, stem cell therapies, biologic skin equivalents, platelet-rich plasma therapy, oxygen therapies, anti-TNF therapy, or negative pressure wound therapy are advanced venous ulcer therapeutic methods that may support the standard of care. Medical devices, such as a muscle pump activator, or intermittent pneumatic compression device, may be especially useful for specific subgroups of patients suffering from VLUs. Some of the above-mentioned technologies require broader evidence of clinical efficacy and are still considered experimental therapies in dermatology.

Sign in / Sign up

Export Citation Format

Share Document